Introduction
Therapeutic strategies cure more than 80% of children with acute lymphoblastic leukemia (ALL), but some patients require intensive treatment and develop complications due to side effects. 1 Furthermore, for adults the ALL survival rate remains below 40%, in part due to the dominant role of the BCR-ABL oncogene in adult ALL cases. 1, 2 In Philadelphia chromosome (Ph 1 ) leukemia, the characteristic t(9;22) chromosomal translocation fuses a breakpoint cluster region (BCR) derived from human chromosome 22 to a portion of the c-ABL proto-oncogene from chromosome 9, leading to the formation of the BCR-ABL fusion oncoproteins p210 BCR-ABL (p210) and p185
BCR-ABL (p185) that are typically detected in chronic myelogenous leukemia (CML) and Ph 1 ALL cells, respectively. 3, 4 Both p185 and p210 encode constitutively active tyrosine kinases essential for cell transformation.
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The treatment of BCR-ABL-expressing CML has been revolutionized by tyrosine kinase inhibitors (TKIs) of BCR-ABL like imatinib (IM), which induces and maintains remission in the majority of CML cases without serious side effects when administered as a single agent. 6 However, ;5% of CML patients per year develop resistance typically due to secondary mutations in the BCR-ABL oncogene. 7 In contrast, the response of Ph 1 B-lineage ALL (B-ALL)
to treatment by TKIs results in short remissions and is typified by rapid outgrowth of drug-resistant clones. 8 As a result, both pediatric and adult Ph 1 ALL patients require maximally intensive combination chemotherapy and stem cell transplants, but even these measures are often unable to achieve long-term survival. 1 Apoptosis is necessary to regulate the proper development and maintenance of tissue homeostasis in metazoans by eliminating damaged or obsolete cells. However, apoptotic dysregulation can lead to a variety of human pathologies including cancer. Intrinsic apoptosis is triggered when signals activate and/or induce BCL-2 homology domain-3 (BH3)-only molecules, promoting BAX and BAK activation facilitating the release of cytochrome c from the mitochondria that initiates apoptosome assembly and drives downstream caspase activation. 9, 10 Genetic loss of both Bax and Bak prevents the induction of intrinsic apoptosis. 9 Antiapoptotic family members such as BCL-2, BCL-X L , BCL-w, BFL-1, and MCL-1 antagonize this process and as a result are often overexpressed to prevent cell death in malignant cells. 11 A mouse model of human Ph 1 B-ALL has been established by transducing Arf-deficient (Arf 2/2 ) mouse bone marrow (BM) cells with either the p210 or p185 fusion proteins generating rapidly growing BCR-ABL-expressing pre-B lineage cells that lose interleukin-7 (IL-7) dependence. 12 Cytokine signaling by IL-7 can overcome the effects of TKI treatment on the leukemic cells, whereas inhibition by a Janus kinase inhibitor blocked IL-7's protective effects. 12 Furthermore, leukemic cells derived from common g-chain-deficient BM were more sensitive in vivo than wild-type leukemic cells to IM treatment. 13 Thus, cytokine signaling can antagonize the effects of TKI treatment.
To identify whether Mcl-1 is a therapeutic target for treating Ph , and Rosa-ERCre T2 mice have been described previously. [14] [15] [16] [17] For in vivo deletion, mice transplanted with p185
1 Rosa-ERCre T2 leukemia received 5 doses of tamoxifen (TAM) (1 mg per dose; Sigma-Aldrich, St. Louis, MO) emulsified in sunflower oil vehicle (Sigma-Aldrich) by gavage. All mice were bred in accordance with St. Jude Children's Research Hospital (SJCRH) animal care and use committee.
Plasmids, expression constructs, and generation of mutants

Mcl-1
GRRL changes glycine-243 to arginine and arginine-244 to leucine in mouse Mcl-1 by site-directed mutagenesis. Mutagenic polymerase chain reaction (PCR) primer sequences are available by request. Human BCL-X L and BCL-2 were from Dr D. Green (SJCRH, Memphis, TN). BCR-ABL (p185) plasmid was from Dr O. Witte (University of California Los Angeles, Los Angeles, CA). Stable cells were generated by retroviral transduction and puromycin selection (2 mg/mL final; Sigma-Aldrich).
Ecotropic retroviral production and cell transduction
Retroviruses were produced as previously described. 18 
BM transplantation
BM was harvested and transduced for 3 hours with retrovirus and 8 mg/mL polybrene in the absence of cytokines and was washed, and 1 million cells were injected into lethally irradiated (1100 rad) C57BL/6 recipients (The Jackson Laboratory, Bar Harbor, ME) by tail-vein intravenous route. Peripheral blood was monitored for leukemia, and recipients were observed for morbidity. Each transplant was performed on at least 2 initial BM infections. For secondary transplants, leukemic BM was mixed 1:1 with control BM and transplanted into lethally irradiated recipients (at least 10 recipients per initial leukemia).
Immunohistochemistry
Specimens were fixed in 10% formalin, paraffin embedded, and sectioned 4 mm thick. Sections were stained with hematoxylin and eosin and deparaffinized, and immunohistochemistry for Pax5 detection was performed using goat antihuman Pax5 (SC1974; Santa Cruz Biotechnology, Dallas, TX,). Goat polymer (GHP 516; BioCare Medical, Concord, CA) with deaminobenzidine detection system (TA125 HDX; ThermoShandon, Kalamazoo, MI) was used for visualization. Representative images from leukemic mice are presented.
Cells and cell culture
Mouse p185
1 Arf 2/2 B-ALL and human Ph 1 cell lines (TOM1, 19 OP-1, 20 and BV173
21
) were grown in RPMI (Life Technologies, Carlsbad, CA) with 20% fetal bovine serum, 55 mM 2-mercaptoethanol, 2 mM glutamine, penicillin, and streptomycin. When indicated, recombinant IL-7 (20 ng/mL; Peprotech, Rocky Hill, NJ) was added to the culture media. IM (Novartis, Basal, Switzerland), dasatinib (DAS) (Bristol-Myers Squibb, New York City, NY), and navitoclax (ABT-263; Selleckchem, Houston, TX) solubilized in dimethylsulfoxide were added at indicated concentrations.
Western blotting, coimmunoprecipitation, and antibodies
Protein expression from cell lysates and immunoprecipitation was performed as previously described. 22 Each immunoblot is representative of at least 3 separate experiments performed independently. The antibodies used were the following: anti-MCL-1 (Rockland Immunochemical, Gilbertsville, PA), anti-BIM (BD Biosciences, Franklin Lakes, NJ), anti-BCL-X L (BD Biosciences), anti-BCL-2 (Clone 6C8), phosphospecific and total STAT5 antisera (Dr J. Ihle, SJCRH), anti-phosphospecific and total ABL antisera (Cell Signaling, Beverly, MA), anti-Cre (EMD Chemical, Billerica, MA), anti-BCL-w (Cell Signaling), anti-BFL-1 (Pierce Biotechnology, Rockford, IL), anti-PARP (Cell Signaling), and antiactin mouse monoclonal (Millipore, Billerica, MA). Secondary antisera were anti-rabbit or anti-mouse horseradish peroxidase conjugated (Jackson ImmunoResearch, West Grove, PA).
Cell death experiments
Cell viability was determined by staining with annexin V-fluorescein isothiocyanate and propidium iodide (PI) (BD Biosciences) and flow cytometry. For experiments on mouse cell lines, each experiment was performed on at least 2 independently generated cells from in vitro-transduced mouse BM. Three separate experiments were performed, each in triplicate. Figure 1A -B). Exposure to either TKI, which blocked STAT5 and BCR-ABL phosphorylation, decreased MCL-1 expression but did not alter BCL-2 or BCL-X L expression ( Figure 1A-B) . The loss of MCL-1 was alleviated by adding exogenous IL-7 to the cultures, suggesting that signaling can bypass drug-dependent inhibition of BCR-ABL signaling and maintain MCL-1 expression ( Figure 1A-B tion. This was due, at least in part, to the failure to express Cre protein due to nonsense mutations in Cre ( Figure 2I ; supplemental Figure 1B ). Additionally, in other leukemic samples we also detected missense mutations that resulted in mutant Cre protein (supplemental Figure 1C) . Thus, when Cre was coexpressed during the transformation with p185, there was a strong selection against Mcl-1 deletion during in vitro and in vivo leukemogenesis.
Analyses of
Requirement for antiapoptotic function in initiation of leukemia in vitro
To assess whether MCL-1 loss induces the death of the cells, BM was isolated from Mcl-1 f/f Bax f/f Bak 2/2 mice for p185-IRES-Cre transduction, and the outgrowth of leukemic cells from the cultures followed ( Figure 3A ). Figure 3A ). In contrast, the outgrowth from Mcl-1 f/f cultures was dramatically delayed ( Figure 3A ). Expression analyses indicated that unlike the p185 only.
For Figure 3E ; supplemental Figure 1D) . Thus, the loss of BIM expression was insufficient to allow the outgrowth of p185 Figure 3A ). Mcl-1 deletion rendered MEFs susceptible to staurosporine-induced death, and ectopic expression of MCL-1 wt rendered them resistant (supplemental Figure 3B) . In contrast, stable expression of the MCL-1 GRRL mutant could not protect the MEFs from apoptosis indicating that the mutant is nonfunctional in antagonizing death (supplemental Figure 3B) . MCL-1 wt coimmunoprecipitated with proapoptotic BIM; however, no interaction was detectable between BIM and MCL-1 GRRL protein (supplemental Figure 3C ). These data demonstrate that the MCL-1 GRRL lacks the ability to sequester proapoptotic modulators, such as BIM, and therefore cannot prevent apoptosis.
To Figure 3F ). In contrast, the expression of MCL-1 GRRL was insufficient to promote the outgrowth of cells from the cultures indicating that MCL-1's antiapoptotic function is required for promoting leukemic initiation in vitro ( Figure 3F ).
Because MCL-1's ability to inhibit cell death appears to be required for leukemic cell survival, we tested whether overexpression of other antiapoptotic BCL-2 family members might suffice to protect the BM cells during in vitro leukemic initiation. only.
For personal use at American Society of Hematology on August 30, 2013. bloodjournal.hematologylibrary.org From these cells lacked MCL-1 expression when they expressed exogenous antiapoptotic cDNAs ( Figure 4D ). Therefore, these data indicate that even transformed BCR-ABL 1 B-ALL cells require endogenous MCL-1 to promote their survival and growth, but that the requirement for MCL-1 can be supplanted by overexpression of other antiapoptotic BCL-2 family members.
In vivo requirement for antiapoptotic MCL-1 function in leukemia maintenance
We Figure 5A ). Strikingly, although the p185-transformed, Mcl-1 f/f Rosa-ERCre T2 vehicle-treated group all succumbed to leukemia (median survival 20 days), the progression of leukemia in the TAM-treated group was significantly delayed (median survival 46 days) with ;40% TAM-treated mice remaining leukemia free for .200 days since leukemia transplant ( Figure 5A ).
At the time of being euthanized, moribund mice from both the TAM-treated and control groups exhibited GFP Figure 5A) . Intriguingly, in some moribund TAM-treated mice, we detected the deletion of 1 Mcl-1 genomic allele but also found mutations in the 59 loxP site of the other (nondeleted) allele ( Figure 5D ; supplemental Figure 5B ). Histopathologically, the leukemia arising in the moribund mice was pathologically similar whether the mice received TAM or vehicle treatment and uniformly expressed Pax5, a marker of B-lineage leukemia ( Figure 5E ; supplemental Figure 3 ). These data indicate that Mcl-1 deletion in vivo delayed leukemia progression and that those TAM-treated recipients that succumbed to disease exhibited selection against Mcl-1 deletion in the leukemic cells.
Potentiation of TKI activity by small-molecule BCL-2 inhibitors in mouse BCR-ABL leukemia
The small-molecule inhibitor navitoclax (ABT-263) specifically inhibits the antiapoptotic function of BCL-2 and BCL-X L and exhibits efficacy in BCL-2-dependent cancers with limited toxicity. [29] [30] [31] However, a common feature mediating tumor cell resistance to navitoclax and its progenitor compound (ABT-737) is the expression of other antiapoptotic proteins, like MCL-1, which are not targeted by these compounds. [32] [33] [34] As MCL-1 expression often correlates with tumor cell resistance to the cell-killing activity of navitoclax, we tested the death sensitivity of in vitro-generated p185 Figure 6A ). Navitoclax has been proposed to promote apoptosis by displacing proapoptotic BH3-only family members from antiapoptotic molecules, thus facilitating proapoptotic effector (BAX and BAK) activation and cell death. 35, 36 To test this hypothesis, in vitro-generated p185 1 Arf 2/2 Mcl-1 wt cells (referred to as BCR-ABL B-ALL cells) were treated with navitoclax and immunoprecipitated with anti-BIM antibodies to measure the BH3-only occupancy of antiapoptotic BCL-2 family members, as BIM interacts with BCL-2, BCL-X L , and MCL-1. 37, 38 As the navitoclax dose increased, the amount of BCL-2 and BCL-X L immunoprecipitating with BIM decreased, and there was a corresponding increase in MCL-1 protein associated with BIM ( Figure 6B ). These data indicated that navitoclax displaced BIM from BCL-2 and BCL-X L and suggest that the liberated BIM could then interact with MCL-1 ( Figure 6B ). BIM is a relevant proapoptotic molecule as Bim-deficient p185-transformed leukemic cells, derived from Bim-conditional BM transduced with p185-IRES-Cre retrovirus, are partially resistant to TKI and navitoclax treatment consistent with previously published reports (supplemental Figure 6) . [24] [25] [26] 35 These data suggest that treatment with navitoclax may be less effective at killing BCR-ABL B-ALL cells because the leukemic cells may have sufficient MCL-1 to "buffer" the release of proapoptotic molecules, such as BIM, from BCL-2 and BCL-X L .
Treatment of BCR-ABL B-ALL cells with TKIs decreased the amount of MCL-1 protein expressed and induced cell death but did not modulate BCL-2, BCL-X L , or BIM expression ( Figure 1A -B and Figure 6C-D) . However, TKI treatment did not disrupt the interaction between BCL-2, BCL-X L , or MCL-1 with proapoptotic BIM as detected by co-immunoprecipitation (Figure 6C-D) . Because TKIs decreased MCL-1 protein expression, we hypothesized that we could potentiate the efficacy of navitoclax on BCR-ABL B-ALL cells by combining navitoclax with TKI treatment to decrease only.
For Figure 6F ) that each induce ;10% apoptosis and coadministered increasing doses of navitoclax. As the navitoclax was increased, we observed potentiation of the TKIs indicating a synergistic effect of combining navitoclax and TKI treatment ( Figure 6E-F) . Growth factor signaling by IL-7 can partially overcome the death induced by TKI treatment; therefore, we tested whether IL-7 could overcome the potentiation of combining TKI treatment and navitoclax. Although exogenous IL-7 treatment reduced the effectiveness of TKI treatment and reduced the killing observed, a statistically significant effect of combining TKIs with navitoclax was observed ( Figure 6E-F ). These data demonstrate that combining TKIs and navitoclax can enhance activity against BCR-ABL B-ALL cells and overcome the resistant effects of growth factor signaling. (Figure 7) . Therefore, among antiapoptotic BCL-2 family members, only MCL-1 expression declines robustly in response to TKI treatment. We hypothesized that we may be able to potentiate the efficacy of navitoclax on the Ph 1 cell line by combining with TKI treatment to decrease MCL-1 expression. Thus, we treated the human Ph 1 cell lines with doses of TKIs that each induced ;10% apoptosis and coadministered increasing navitoclax doses ( Figure 7 ). As navitoclax was increased in the cultures, we observed a potentiation of the TKIs to induce apoptosis ( Figure 7 ). These data indicate that like our observations in mouse BCR-ABL cell lines, combining TKIs and navitoclax in human Ph 1 cell lines can also lead to enhanced activity. Although MCL-1 expression is most overtly decreased in response to TKI treatment, it is possible that combining TKI and navitoclax may affect targets other than MCL-1 leading to cell death. These data 
Discussion
It has been reported that genetic deletion of Bcl2l1 (encoding the BCL-X antiapoptotic protein) in a mouse model of BCR-ABL B-ALL did not adversely affect leukemogenesis and paradoxically resulted in the increased proliferation of the BCL-X-deficient B-ALL cells. only.
For personal use at American Society of Hematology on August 30, 2013. bloodjournal.hematologylibrary.org From MCL-1 is striking as both B-lineage progenitors and leukemic cells simultaneously express other antiapoptotic molecules; however, the endogenous expression of these molecules is insufficient to allow survival of the cells without MCL-1.
One potential rationale for the absolute dependence on MCL-1 is that it possesses unique functions that cannot be compensated for by other antiapoptotic BCL-2 family members. 18 However, although MCL-1 may have additional roles beyond preventing cell death, our data demonstrate that either loss of both proapoptotic effectors (BAX and BAK) or ectopic expression of human BCL-2 or human BCL-X L can rescue the survival and growth of Mcl-1-deleted leukemic cells. Therefore, the primary function of MCL-1 in this mouse model of Ph 1 B-ALL is to block apoptosis.
Our results are consistent with a model in which the "pool" of antiapoptotic MCL-1 in cells is the critical regulator of cellular survival. Signaling, either through either cytokine receptors or by the BCR-ABL oncofusion, promotes MCL-1 expression to counter proapoptotic molecules in the cells. When signaling diminishes, either due to a lack of cytokines or after TKI treatment, MCL-1 levels decrease becoming insufficient to counter the proapoptotic molecules. Supporting this model, treatment of primary chronic lymphocytic leukemia with TKIs also reduces MCL-1 expression. 40 In contrast, when exogenous BCL-2 and BCL-X L are overexpressed in the cells, it expands the "pool" of antiapoptotic modulators allowing the cells to counter proapoptotic expression despite a loss of MCL-1 function.
A dominant role for MCL-1 in promoting leukemic cell survival is also seen in mouse models of acute myelogenous leukemia (AML). 41, 42 Strikingly, whether the AML cells were driven by c-Myc, MLL-ENL, MLL-AF9, Mixl1, AML1-ETO9a, or Hox19, the resultant leukemia were similarly dependent on MCL-1. 41, 42 Similar data exist for human CML cells driven by the BCR-ABL oncofusion. 43 Furthermore, in these models, MCL-1's primary function is to prevent apoptosis as ectopic expression of other antiapoptotic family members promoted leukemia survival in these models. 41, 42 Therefore, strategies to inhibit MCL-1's antiapoptotic function would be predicted to be therapeutically beneficial. However, MCL-1 is an important modulator of the survival of a number of normal cell lineages including, but not limited to, hematopoietic lineages. 14, 44, 45 Thus, it may be difficult to inhibit MCL-1 in malignant cells without inducing toxicity in normal cells. An alternative strategy may be to modulate MCL-1 expression levels to reduce the size of the antiapoptotic "pool" in cancer cells to foster lethality of malignant cells without inducing toxicity to normal cell lineages.
MCL-1 is a transcriptional target of cytokine and growth factor signaling. 14, 44, 46 Additionally, MCL-1 protein is short lived being a proteasome substrate. 47, 48 MCL-1 degradation is also regulated, as posttranslational modifications play a critical role in regulating its elimination. 49, 50 MCL-1 can also undergo ubiquitinylation-independent protease degradation. 22 MCL-1's labile nature raises the possibility that it may be possible to simply perturb its expression. Indeed, combining inhibitors of cellular signaling to potentiate the death induced by TKIs has already shown promise in CML models, [51] [52] [53] and in some cases, these combined therapies decreased MCL-1 expression. 54 Identification of these pathways downstream of BCR-ABL signaling may identify further ways by which MCL-1 expression levels can be modulated in leukemic cells. When used alone, navitoclax is relatively ineffective at treating BCR-ABL B-ALL cell lines in vitro, presumably as it displaces proapoptotic molecules (ie, BIM and others) from BCL-2 and BCL-X L , but the liberated proapoptotic molecules can still be sequestered by MCL-1. 32, 33 However, when TKIs are combined with navitoclax, cell death is potentiated as there is less MCL-1 available to sequester proapoptotic molecules. Although we cannot rule out the possibility that combining these inhibitors may have effects beyond merely modulating MCL-1 function, MCL-1 is the only antiapoptotic molecule whose expression is significantly altered by TKI treatment. Our synergy experiments are similar to those in BCR-ABL models of CML or gastrointestinal stromal cell tumor cells in which combinatorial treatment with TKIs and BH3 mimetics like navitoclax has been shown to be synergistic. 26, 55, 56 MCL-1 is a critical prosurvival molecule required to promote the survival of B-cell progenitor populations during BCR-ABL transformation as well as for the continued survival of the BCR-ABL B-ALL cells. These findings highlight the potential for targeting MCL-1 protein expression and function in treating this BCR-ABL B-ALL. We submit that although specific MCL-1 inhibitors may be effective at treating BCR-ABL leukemia, approaches that would alter the expression levels of MCL-1 should also be effective at sensitizing this leukemia to other treatment modalities including BCL-2 inhibitors such as navitoclax. 
